Claims
- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2; (b) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and (c) a polynucleotide fragment of the polynucleotide of (a) or (b).
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 2 which encodes the polypeptide as set forth in SEQ ID NO:2.
- 4. The polynucleotide of claim 2 comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to 1953.
- 5. The polynucleotide of claim 2 comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 200 to 1953.
- 6. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide which encodes a mature polypeptide encoded by the DNA contained in ATCC Deposit No. 75855; (b) a polynucleotide which encodes a polypeptide expressed by the DNA contained in ATCC Deposit No. 75855; (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).
- 7. A vector containing the DNA of claim 2.
- 8. A host cell genetically engineered with the vector of claim 7.
- 9. A process for producing a polypeptide comprising expressing from the host cell of claim 8 the polypeptide encoded by said DNA.
- 10. A process for producing cells capable of expressing a polypeptide comprising transforming or transfecting the cells with the vector of claim 7.
- 11. A polypeptide selected from the group consisting of:
(a) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; (b) a polypeptide comprising amino acid 1 to amino acid 262 of SEQ ID NO:2; and (c) a polypeptide encoded by the cDNA of ATCC Deposit No. 75855 and fragments, analogs and derivatives of said polypeptide.
- 12. A compound effective as an agonist for the polypeptide of claim 11.
- 13. A compound effective as an antagonist against the polypeptide of claim 11.
- 14. A method for the treatment of a patient having need of hABH comprising:
administering to the patient a therapeutically effective amount of the polypeptide of claim 11.
- 15. The method of claim 14 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 16. A method for the treatment of a patient having need of hABH comprising administering to the patient a therapeutically effective amount of the compound of claim 12.
- 17. A method for the treatment of a patient having need to inhibit hABH comprising: administering to the patient a therapeutically effective amount of the antagonist of claim 13.
- 18. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 11 comprising determining a mutation in the nucleic acid sequence encoding said polypeptide.
- 19. A diagnostic process comprising analyzing for the presence of the polypeptide of claim 11 in a sample derived from a host.
- 20. A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of claim 11 comprising:
(a) contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and (b) determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 09/296,623, filed Apr. 23, 1999, which is a divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 09/023,327, filed Feb. 13, 1998 (now U.S. Pat. No. 5,929,225, issued on Jul. 27, 1999), which is a divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 08/783,266, filed Jan. 15, 1997 (now U.S. Pat. No. 5,747,312, issued on May 5, 1998), which is a divisional of and claims priority under 35 U.S.C. §120 to U.S. application Ser. No. 08/463,975, filed Jun. 5, 1995 (now U.S. Pat. No. 5,618,717, issued on Apr. 8, 1997), which is a continuation-in-part of and claims priority under 35 U.S.C. §120 to International Application No. PCT/US94/12058, filed Oct. 21, 1994. Each of the above referenced applications is hereby incorporated by reference herein in its entirety.
Divisions (4)
|
Number |
Date |
Country |
Parent |
09296623 |
Apr 1999 |
US |
Child |
10322780 |
Dec 2002 |
US |
Parent |
09023327 |
Feb 1998 |
US |
Child |
09296623 |
Apr 1999 |
US |
Parent |
08783266 |
Jan 1997 |
US |
Child |
09023327 |
Feb 1998 |
US |
Parent |
08463975 |
Jun 1995 |
US |
Child |
08783266 |
Jan 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US94/12058 |
Oct 1994 |
US |
Child |
08463975 |
Jun 1995 |
US |